Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) EPS (Weighted Average and Diluted) (2021 - 2026)

Cogent Biosciences' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.53 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 1.92% to -$0.53 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.17 through Mar 2026, up 99.57% year-over-year, with the annual reading at -$2.16 for FY2025, 11.34% down from the prior year.
  • EPS (Weighted Average and Diluted) came in at -$0.53 for Q1 2026, up from -$0.61 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.11 in Q4 2022 to a low of -$501.16 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.53 (2025), against an average of -$43.87.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 117.74% in 2022 and then crashed 96276.92% in 2024.
  • Cogent Biosciences' EPS (Weighted Average and Diluted) stood at $0.11 in 2022, then tumbled by 572.73% to -$0.52 in 2023, then plummeted by 96276.92% to -$501.16 in 2024, then skyrocketed by 99.88% to -$0.61 in 2025, then grew by 13.11% to -$0.53 in 2026.
  • Per Business Quant, the three most recent readings for COGT's EPS (Weighted Average and Diluted) are -$0.53 (Q1 2026), -$0.61 (Q4 2025), and -$0.5 (Q3 2025).